(2023)
Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
BREAST.
72,
(2023)
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
ESMO OPEN.
8,
6
(2023)
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.
CANCERS.
15,
22
(2023)
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
NATURE COMMUNICATIONS.
14,
1
(2023)
A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
21
(2023)
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach.
RADIATION ONCOLOGY.
18,
1
(2023)
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer.
CANCERS.
15,
19
(2023)
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY.
18,
9
(2023)
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
CLINICAL CANCER RESEARCH.
29,
16
(2023)
Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study.
CANCERS.
15,
13
(2023)
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
CANCERS.
15,
13
(2023)
Efficacy of the PRO-CTCAE mobile application for improving patient participation in symptom management during cancer treatment: a randomized controlled trial.
SUPPORTIVE CARE IN CANCER.
31,
6
(2022)
Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY.
87,
4
(2022)
Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.
FRONTIERS IN ONCOLOGY.
12,
(2022)
Development and Validation of Digital Health Technology Literacy Assessment Questionnaire.
JOURNAL OF MEDICAL SYSTEMS.
46,
2
(2021)
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study.
BLOOD CANCER JOURNAL.
11,
12
(2021)
Real-world data from a refractory triple-negative breast cancer cohort selected using a clinical data warehouse approach.
CANCERS.
13,
22
(2021)
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?.
FRONTIERS IN ONCOLOGY.
11,
(2021)
Elevated level of nerve growth factor (Ngf) in serum-derived exosomes predicts poor survival in patients with breast cancer undergoing neoadjuvant chemotherapy.
CANCERS.
13,
21
학술회의논문
(2012)
Effects of Statin on triple-negative breast cancer(TNBC) with Ets-1 overexpression.
San Antonio Breast Cancer Syposium.
미국
(2012)
Validation and comparison of CS-IHC4 score with a nomogram based on Ki67 index, Adjuvant! Online, and St. Gallen risk stratification to predict recurrence in early Hormone Receptor(HR)-positive brease cancers.
San Antonio Breast Cancer Syposium.
미국
(2012)
Phase II trial TS-1 in combination with oxaliplatin (SOX) in metastatic breast cancer (MBC) previously treated iwth anthracycline ans taxane chemotherapy [TORCH].
한국임상암학회 제5차 학술대회.
대한민국
(2012)
Quality of life (QoL) in Metastatic Breast Cancer Patients with Maintenance Paclitaxel plus Gemcitabine (PG) Chemptherapy: Rwsults from Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation.
한국임상암학회 제5차 학술대회.
대한민국
(2012)
A Phase III, Multicenter, randomized Trial of Maintenance Versus Observation After Achieving Clinical Response in Patients With Metastatic Breast cancer Who Received 6 Cycles of Gemcitabine Plus Paclitaxel as First-line Chemotherapy.
The 10th Annual Meeting of JSMO.
일본
(2012)
Time to brain metastasis(TTBM) from initial diagnosis of distant metastasis in breast cancer: Prediction of TTBM according to breast cancer subtypes ans treatment effect.
The 10th Annual Meeting of JSMO.
일본
(2011)
Adjuvant Trastuzumab Effect on HER2-Positive Breast Cancers
According to Hormonal Receptor (HR) Status: Crosstalk between ER and EGFR/HER2 Pathway May Prevent Trastuzumab from Improving Outcomes in HER2-Positive and HR-Positive Breast Cancers..
Cancer Research.
미국
(2011)
Nomogram To Predict Recurrence and To Avoid Unnecessary
Adjuvant Chemotherapy Based on Ki67 Index and ER Status
in Hormone Receptor (HR)-Positive Breast Cancers with Low
Number of Nodal Metastases (≤3) (NCT01273415).
Cancer Research.
미국
(2011)
Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX)
in Patients with Metastatic Breast Cancer (MBC) Previously
Treated with Anthracycline and Taxane Chemotherapy [TORCH]
[Korean Cancer Study Group (KCSG) BR07-03]..
Cancer Research.
미국
(2011)
Small Node-Negative (T1b-cN0) Invasive Hormone Receptor
(HR)-Positive Breast Cancers: Is There a Population Which Might
Have Benefit from Adjuvant Chemotherapy?.
Cancer Research.
미국
(2011)
Abjuvant Trastuzumab Effect on HER2-Positive Breast Cancers According to Hormonal Receptor(HR)State: Cross-talk between HER2 and ER pathway May Prevent Trastuzumab from Improving Outcomes in HER2+ve/HR+ve Breast Cancers.
한국임상암학회지.
대한민국
(2011)
Small Node-Negative(T1b-cNO) Invasive Hormone Receptor (HR)-Positive Breast Cancers: Is there a population which might have benefit from adjuvant chemotherapy?.
한국임상암학회지.
대한민국
(2011)
Comparison The Nomogram to Other Predictive Tolls (Adjuvant! Online,St.Galen Consensus,And CS-IHC4) In Hormone Receptoe (HR)-Positive Breast Cancers.
Journal of Breast Cancer.
대한민국
(2011)
Proposal of a Breast Cancer-Specific Prognostic Model And a Nomogram to Predict Outcomes for with Brain Metastates(BM) From Breast Cancer.
Journal of Breast Cancer.
대한민국
(2011)
CA 15-3 Elevations According to Breast Cancer Subtypes at Initial Diagnosis of Metastatic Breast Cancer (MBC).
Cancer Research and Treatment.
대한민국
(2011)
Fluropyrimidine/platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients.
Cancer Research and Treatment.
대한민국
(2011)
Prognostic Impact on FOXP3 Expression in Triple Negative Breast Cancer (TNBC).
CANCER RESEARCH AND TREATMENT.
대한민국
(2011)
Prognostic Model for Patients with Brain Metastases (BM) from Breast Cancer.
CANCER RESEARCH AND TREATMENT.
대한민국
(2011)
Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC)..
Journal of Clinical Oncology.
미국
(2011)
Prognostic index for patients with brain metastases from breast cancer: A validation and refinement of the breast-specific graded prognostic assessment (GPA) index.
Journal of Clinical Oncology.
미국
